AstraZeneca, CSPC ink drug R&D deal
AstraZeneca and CSPC Pharmaceutical have signed a research deal worth up to USD 5.3 billion to co-develop oral therapies for chronic and immunological diseases. CSPC will lead discovery in China using AI-driven tools, while AstraZeneca gains global licensing rights. The partnership follows AstraZeneca’s USD 2.5 billion Beijing investment in March.